Organon & Co (NYSE: OGN) kicked off on Tuesday, up 0.28% from the previous trading day, before settling in for the closing price of $7.11. Over the past 52 weeks, OGN has traded in a range of $6.18-$17.23.
Healthcare Sector giant saw their annual sales slid by -23.49% over the last five years. While this was happening, its average annual earnings per share was recorded -7.86%. With a float of $258.95 million, this company’s outstanding shares have now reached $259.98 million.
Organon & Co (OGN) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Drug Manufacturers – General Industry. The insider ownership of Organon & Co is 0.40%, while institutional ownership is 77.99%. The most recent insider transaction that took place on Nov 12 ’25, was worth 501,755. In this transaction Executive Chair of this company bought 65,400 shares at a rate of $7.67, taking the stock ownership to the 77,869 shares. Before that another transaction happened on May 14 ’25, when Company’s Director bought 12,469 for $8.07, making the entire transaction worth $100,591. This insider now owns 12,469 shares in total.
Organon & Co (OGN) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 0.9 earnings per share (EPS), higher than consensus estimate (set at 0.87) by 0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.01 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -7.86% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.52% during the next five years compared to -23.49% drop over the previous five years of trading.
Organon & Co (NYSE: OGN) Trading Performance Indicators
Take a look at Organon & Co’s (OGN) current performance indicators. Last quarter, stock had a quick ratio of 1.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.29. Likewise, its price to free cash flow for the trailing twelve months is 2.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.92, a number that is poised to hit 0.76 in the next quarter and is forecasted to reach 3.96 in one year’s time.
Technical Analysis of Organon & Co (OGN)
Analysing the last 5-days average volume posted by the [Organon & Co, OGN], we can find that recorded value of 3.4 million was lower than the volume posted last year of 4.75 million. As of the previous 9 days, the stock’s Stochastic %D was 77.62%.
During the past 100 days, Organon & Co’s (OGN) raw stochastic average was set at 18.59%, which indicates a significant decrease from 51.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.22 in the past 14 days, which was lower than the 0.34 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.34, while its 200-day Moving Average is $9.66. Now, the first resistance to watch is $7.21. This is followed by the second major resistance level at $7.28. The third major resistance level sits at $7.34. If the price goes on to break the first support level at $7.08, it is likely to go to the next support level at $7.02. Should the price break the second support level, the third support level stands at $6.95.
Organon & Co (NYSE: OGN) Key Stats
The company with the Market Capitalisation of 1.85 billion has total of 259,983K Shares Outstanding. Its annual sales at the moment are 6,403 M in contrast with the sum of 864,000 K annual income. Company’s last quarter sales were recorded 1,602 M and last quarter income was 160,000 K.
